NCT00286793View on ClinicalTrials.gov

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Prostate Cancer
Interventions
DRUG

AT-101

Oral

Trial Locations (13)

Unknown

Hot Springs

Fort Meyers

Chicago

Fridley

Albuquerque

Syracuse

Wilmington

Portland

Hilton Head Island

Germantown

Memphis

Nashville

Richardson

Sponsors
All Listed Sponsors
lead

Ascenta Therapeutics

INDUSTRY

NCT00286793 - Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC | Biotech Hunter | Biotech Hunter